Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease.

Brief Summary

Type:
Head and Neck Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06589804

Study #:
STUDY00161298

Start Date:
Mar 11, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06589804

View Complete Trial Details & Eligibility at ClinicalTrials.gov